Use of Anti-IL-6 Biologics in Rheumatoid Arthritis Patients in Wales
Author Information
Author(s): Roxanne Cooksey, Jonathan Kennedy, Muhammad Rahman, Sinead Brophy, Ernest Choy
Primary Institution: Cardiff University
Hypothesis
What factors are associated with the initiation and discontinuation of anti-IL-6 biologic DMARDs compared to non-anti-IL-6 biologics in rheumatoid arthritis patients?
Conclusion
Comorbidities, history of infection, and kidney disease were associated with choosing anti-IL-6 bDMARDs in biologic-naïve RA patients in Wales.
Supporting Evidence
- 95.7% of patients received conventional synthetic DMARDs.
- 36.2% of patients were treated with bDMARDs.
- 6.5% of biologic-naïve patients were treated with anti-IL-6 bDMARDs.
- Treatment discontinuation was higher in non-anti-IL-6 bDMARD-treated patients.
Takeaway
Doctors in Wales found that patients with certain health issues are more likely to be given a specific type of medicine for arthritis, and those patients tend to stick with their treatment better.
Methodology
A retrospective cohort study using electronic health records from the Secure Anonymised Information Linkage Databank, analyzing treatment initiation, discontinuation, and clinical outcomes.
Potential Biases
Potential underpowering to detect associations due to low numbers of patients on anti-IL-6 bDMARDs.
Limitations
The cohort may not represent early or less severe rheumatoid arthritis patients, and the absence of certain clinical data may limit findings.
Participant Demographics
Mean age of 62 years, 71.6% female, mean disease duration of 6.3 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 1.1, 17.8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website